22 January 2021 - The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a ...
22 January 2021 - Public comment period now open until 18 February 2021; requests to make oral comment during public meeting ...
15 January 2021 - After correcting an input to the cost-effectiveness model, ICER’s health-benchmark price benchmark range for nadofaragene firadenovec has ...
17 December 2020 - Independent appraisal committee determines current evidence is adequate to demonstrate that nadofaragene firadenovec and oportuzumab monatox ...
10 December 2020 - Report will be subject of New England CEPAC meeting in July 2021; draft scoping document open to ...
2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...
30 November 2020 - Public comment period now open until 5 January 2021; requests to make oral comment during public meeting ...
30 November 2020 - The Institute for Clinical and Economic Review today formally launched ICER Analytics, a new cloud-based platform that ...
20 November 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of emicizumab over factor ...
12 November 2020 - Public comment period on preliminary draft now open until 11 December 2020; requests to make oral comment ...
10 November 2020 - Based on an analysis of four studies evaluating remdesivir’s influence on mortality, ICER has concluded that the ...
3 November 2020 - Cost effectiveness analysis is an important tool for informing treatment coverage and pricing decisions, yet no consensus ...
6 November 2020 - The evidence has significant limitations, and no firm estimate of net health benefit versus best supportive care ...
6 November 2020 - The available evidence on the benefits of reSET-O, Connections, and DynamiCare has substantial limitations and can ...
2 November 2020 - New members’ broad leadership experience — spanning biomedical policymaking and consumer advocacy for ageing populations — will ...